TY - JOUR T1 - EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer JO - Annals of Oncology UR - http://dx.doi.org/10.1093/annonc/mdu269 PY - 2014/07/23 AU - Heymach JV AU - Lockwood SJ AU - Herbst RS AU - Johnson BE AU - Ryan AJ ED - DO - DOI: 10.1093/annonc/mdu269 PB - Elsevier BV VL - 25 IS - 10 SP - 1941 EP - 1948 Y2 - 2025/05/07 ER -